The parties will partner for the development of an affordable Ebola-Zaire vaccine. Credit: SK bioscience.

SK bioscience has signed an agreement with vaccines and biologics research and development organisation Hilleman Laboratories Singapore for the co-development of a second-generation vaccine candidate against the Ebola-Zaire virus.

The companies will partner to develop an affordable vaccine to bolster manufacturing output and boost the thermostability of the product.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

This approach will increase the supply of and access to the Ebola vaccine across the globe.

SK bioscience and Hilleman will acquire capabilities and knowledge for using the recombinant vesicular stomatitis virus vector technology platform to develop vaccines for treating viral infectious diseases.

SK bioscience CEO Jaeyong Ahn stated: “Developing a vaccine to prevent viruses causing diseases with a high fatality rate, such as Ebola-Zaire, is an essential task for us to protect humanity.

See Also:

“By co-operating with Hilleman Laboratories for a successful development of the second-generation Zaire Ebolavirus vaccine, we will contribute to overcoming the Ebola-Zaire disease burden and expand our cooperation with global companies and institutions.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In October 2022, the parties entered a memorandum of understanding to jointly develop new vaccines and technology platforms.

The alliance agreed to use the manufacturing expertise of SK bioscience and Hilleman for end-to-end vaccine studies and vaccine platform development. 

Hilleman Laboratories CEO Dr Raman Rao stated: “Developing vaccines that are more affordable and accessible is core to our mission.

“Our collaboration with SK biosciences on such an impactful vaccine programme will allow us to create positive outcomes for global public health, especially in affected regions of Central and Western Africa.”

In August 2023 SK Bioscience collaborated with Vaxxas for the development of a typhoid conjugate vaccine that can be delivered using a needle-free patch.